According to Gram Research analysis, a cholesterol-related molecule called 7α,25-OHC activates a receptor named GPR183 that converts immune cells into tumor protectors, allowing cancer to hide from the body’s defenses. In gastric cancer patients, higher levels of this pathway correlated with advanced disease and poor survival. When researchers blocked GPR183 in mice, tumors grew slower and the immune system fought back more effectively.
Scientists discovered a hidden pathway that helps tumors escape the body’s natural defenses. The key player is a cholesterol-related molecule called 7α,25-OHC that sends signals through a receptor named GPR183, which tells immune cells called Tregs to become suppressors instead of fighters. In gastric cancer patients, this pathway was linked to more advanced disease and shorter survival times. When researchers blocked this pathway in mice with tumors, the immune system fought back better and cancer growth slowed. This discovery could lead to new cancer treatments that work alongside existing immunotherapy drugs.
Key Statistics
A 2026 study published in Science Advances found that GPR183+ regulatory T cells in gastric cancer patients correlated with advanced disease stage and significantly reduced survival outcomes.
In laboratory mice, conditional deletion of GPR183 specifically in CD4+ T cells and regulatory T cells prevented high-cholesterol-diet-induced tumor growth and restored CD8+ T cell anti-tumor function.
Blocking GPR183 prevented therapy-induced regulatory T cell expansion in tumor models, suggesting the pathway enables tumors to adapt to immunotherapy by generating more suppressor cells.
The 7α,25-OHC-GPR183 signaling axis activates the AXL-JAK2-STAT5 pathway to reinforce Foxp3 expression, the master regulator that makes immune cells suppress tumor-fighting responses.
The Quick Take
- What they studied: How cancer tumors use cholesterol metabolism to suppress the immune system and escape detection
- Who participated: Gastric cancer patients whose tumor samples were analyzed, plus laboratory mice with implanted tumors used to test blocking the pathway
- Key finding: A cholesterol molecule (7α,25-OHC) activates a receptor (GPR183) that converts immune cells into tumor-protecting suppressors, and blocking this pathway restored immune function and slowed tumor growth
- What it means for you: This research identifies a new target for cancer treatment that could make existing immunotherapy drugs work better, though human trials are still needed to confirm safety and effectiveness
The Research Details
Researchers used multiple approaches to understand this immune-suppression pathway. First, they analyzed tumor samples from gastric cancer patients to see if the GPR183 receptor appeared more frequently in advanced cancers. Second, they used laboratory mice with engineered tumors to test what happened when they removed the GPR183 gene specifically from immune cells. Third, they studied the molecular signals inside cells to understand exactly how the cholesterol molecule communicates with immune cells to change their behavior. This combination of patient data, animal models, and molecular analysis allowed them to build a complete picture of how the pathway works.
The researchers also tested whether blocking this pathway could improve the effectiveness of anti-PD-1 immunotherapy, a type of cancer treatment that helps the immune system recognize and attack tumors. They examined how the immune system responded when the GPR183 pathway was blocked, measuring whether more tumor-fighting cells appeared and whether tumor growth slowed down.
This multi-layered approach is important because it connects observations in real cancer patients with controlled experiments that prove cause-and-effect relationships.
Understanding how tumors suppress immunity is crucial for developing better cancer treatments. Many patients don’t respond well to current immunotherapy drugs because their tumors have learned to hide from the immune system. By identifying the specific molecular pathway that enables this hiding, researchers can design drugs to block it and restore the immune system’s ability to fight cancer.
This research was published in Science Advances, a highly respected peer-reviewed journal. The study combined multiple evidence types: human patient data, animal models with genetic modifications, and detailed molecular analysis. The findings showed consistent results across different experimental approaches, which strengthens confidence in the conclusions. However, the animal studies used laboratory mice, which don’t always behave identically to human biology, so human clinical trials would be needed to confirm these results in actual patients.
What the Results Show
The research identified that a cholesterol-related molecule called 7α,25-OHC acts as a chemical signal that tells immune cells to become suppressors. This molecule binds to a receptor called GPR183, which is found on specialized immune cells called Tregs (regulatory T cells). When this binding occurs, it activates a chain of molecular signals inside the cell that strengthens the cell’s suppressive identity, making it better at protecting the tumor from attack.
In gastric cancer patients, tumors with higher levels of GPR183-positive Tregs were associated with more advanced disease and worse survival outcomes. This suggests that this pathway is actively used by real tumors to escape immune detection. When researchers removed the GPR183 gene from immune cells in mice with tumors, the mice’s immune systems fought back more effectively. Tumor growth slowed significantly, and more tumor-fighting CD8+ T cells appeared in the tumor microenvironment.
The molecular mechanism involves a signaling pathway called AXL-JAK2-STAT5. When 7α,25-OHC binds to GPR183, it activates this pathway, which then strengthens the expression of a protein called Foxp3. Foxp3 is the master switch that makes Tregs act as suppressors. By understanding this chain of events, researchers identified multiple points where drugs could potentially intervene to break the cycle.
When researchers tested blocking GPR183 alongside anti-PD-1 immunotherapy (a standard cancer treatment), the combination showed modest improvements in tumor control in some mouse models. Additionally, blocking GPR183 prevented the tumor from expanding its suppressor cell population in response to the immunotherapy.
The research showed that the cholesterol molecule 7α,25-OHC is produced by stromal cells (support cells in the tumor) that express a protein called Vimentin. This means the tumor’s own supporting tissue actively generates the suppressive signal. The study also demonstrated that the GPR183 pathway is specifically required for the expansion of Tregs when animals consume a high-cholesterol diet, suggesting that dietary factors may influence this immune-suppression mechanism. Additionally, the research found that blocking this pathway could prevent therapy-induced Treg expansion, meaning tumors couldn’t adapt to immunotherapy by creating more suppressor cells.
Previous research established that Treg accumulation in tumors is a major barrier to effective immunotherapy, but the specific metabolic signals driving this accumulation were not well understood. This study fills that gap by identifying the cholesterol-7α,25-OHC-GPR183 axis as a key metabolic checkpoint. The findings build on earlier work showing that metabolic pathways influence immune cell behavior, but this is the first clear demonstration of how cholesterol metabolism specifically controls Treg suppressive function in the tumor microenvironment. The connection to AXL-JAK2-STAT5 signaling provides a mechanistic link between cholesterol metabolism and established immune-suppression pathways.
The study primarily used laboratory mice, which have immune systems that don’t perfectly match human biology. The human data came from gastric cancer patients, so it’s unclear whether these findings apply equally to other cancer types. The sample size of human patients analyzed was not specified in the abstract. The blocking of GPR183 showed only modest improvements when combined with anti-PD-1 therapy in some mouse models, suggesting the pathway may be one of several mechanisms tumors use to escape immunity. The research was conducted in controlled laboratory settings, and real-world factors like the complexity of human tumors and individual genetic variation could affect how well these findings translate to clinical practice. Additionally, the long-term safety and effectiveness of GPR183-blocking drugs in humans remains unknown.
The Bottom Line
Based on this research, future cancer treatments may include drugs that block the GPR183 receptor or the 7α,25-OHC signaling pathway. These drugs could potentially be combined with existing immunotherapy treatments like anti-PD-1 therapy to improve effectiveness. However, these recommendations are based on laboratory and animal studies. Confidence level: Moderate for the basic science findings, but Low for clinical recommendations until human trials are completed. Patients should not change their cholesterol intake based on this research alone, as the high-cholesterol diet effect was only observed in mice.
This research is most relevant to gastric cancer patients and researchers developing new cancer immunotherapies. It may also apply to other cancer types that use similar immune-suppression mechanisms, though this would need to be tested. Patients currently undergoing immunotherapy who aren’t responding well might eventually benefit from GPR183-blocking drugs, but these don’t yet exist in clinical practice. People without cancer should not make dietary changes based on this research, as the connection between dietary cholesterol and this immune pathway has only been demonstrated in mice.
If GPR183-blocking drugs are developed, they would need to go through several phases of clinical trials before becoming available to patients. This typically takes 5 to 10 years from the time a promising drug candidate is identified. Patients in early-stage clinical trials might see benefits within months, but widespread availability would take considerably longer. The research suggests that blocking this pathway could enhance existing immunotherapy, so benefits might appear as improved tumor response rather than a completely new treatment effect.
Frequently Asked Questions
How does cholesterol help cancer hide from the immune system?
Cholesterol is converted into a molecule called 7α,25-OHC, which sends signals through a receptor called GPR183 on immune cells. This signal tells immune cells to become suppressors instead of fighters, allowing tumors to escape detection. This pathway was discovered in gastric cancer patients and confirmed in laboratory studies.
Can blocking GPR183 improve cancer immunotherapy?
Research shows that blocking GPR183 modestly enhanced anti-PD-1 immunotherapy effectiveness in some mouse tumor models and prevented tumors from expanding their suppressor cell population in response to treatment. However, human clinical trials are needed to confirm whether GPR183-blocking drugs will improve outcomes in cancer patients.
Should I change my diet if I have gastric cancer or family history?
This research showed that high-cholesterol diets increased this immune-suppression pathway in mice, but human studies haven’t confirmed this effect. Don’t make major dietary changes based solely on this research. Discuss cholesterol management and diet with your oncologist, who can provide personalized recommendations based on your specific situation.
When will GPR183-blocking drugs be available for cancer patients?
This research identifies GPR183 as a potential drug target, but no GPR183-blocking medications currently exist for cancer treatment. If drug development begins now, clinical trials would likely take 5 to 10 years before such treatments become widely available to patients.
Does this research apply to all cancer types or just gastric cancer?
This study focused on gastric cancer in human samples and used general tumor models in mice. The GPR183 pathway may affect other cancers similarly, but this would need to be tested separately. Researchers will likely investigate whether these findings apply to breast cancer, lung cancer, and other common types.
Want to Apply This Research?
- Track cholesterol levels and immune-related symptoms (fatigue, infection frequency, inflammation markers) monthly if you have a cancer diagnosis or family history of gastric cancer. Record any immunotherapy treatments and their timing to correlate with immune function changes.
- If you have gastric cancer or are at risk, work with your oncologist to monitor cholesterol levels and discuss whether dietary modifications might support your immune system. Log any new immunotherapy treatments in your app and track side effects and response patterns to share with your care team.
- Establish a baseline of cholesterol levels, immune markers (if available through your doctor), and overall energy levels. Check these quarterly and note any changes alongside cancer treatment timelines. This data can help your medical team understand how your body is responding to therapy and whether emerging GPR183-blocking treatments might be appropriate for you in the future.
This research describes laboratory and animal studies identifying a potential new cancer treatment target. These findings have not yet been tested in human clinical trials. Do not change your cholesterol intake, cancer treatment, or medical care based on this research alone. If you have gastric cancer, are at risk for cancer, or are currently undergoing immunotherapy, discuss these findings with your oncologist or healthcare provider. They can help you understand how this research might eventually apply to your specific situation and whether you should participate in future clinical trials testing GPR183-blocking drugs.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.